| Literature DB >> 1571071 |
Abstract
Selegiline (Eldepryl), recently approved as an adjunct to levodopa-carbidopa (Sinemet), was administered to eight patients with Parkinson's disease in an open-label study. Many side effects were seen pertinent in particular to the elderly patient. Urinary retention was precipitated in two gentlemen. We advise that this medication be used with caution in the parkinsonian patient.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1571071 DOI： 10.1177/002383099200500105
Source DB: PubMed Journal: J Geriatr Psychiatry Neurol ISSN： 0891-9887 Impact factor: 2.680